



ZW

MAIL STOP - PCT
Attorney Docket No.: 27627U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ARBER, et al.

Application No.: 10/589,000

Filed: August 10, 2006

Intl. Application No.: PCT/IL2005/000173

Intl. Filing Date: February 10, 2005

Title: COMPOSITIONS FOR TREATMENT OF CANCER AND INFLAMMATION
WITH CURCUMIN AND AT LEAST ONE NSAID

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Transmittal Letter;
- 2) Information Disclosure Statement;
- 3) PTO Form 1449 citing 10 references with 7 references attached.

Respectfully submitted,
NATH & ASSOCIATES PLLC

By:


Gary M. Nath, Reg. No. 26,965
Susanne M. Hopkins, Reg. No. 33,247
Customer No. 20529

Date: January 4, 2007

NATH LAW GROUP
112 South West Street
Alexandria, VA 22314
Phone: 703-548-6284
Fax: 703-683-8396
GMN/SMH/dd:IDS_FRT&Trans



MAIL STOP - PCT
Attorney Docket No.: 27627U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ARBER, et al.


Application No.: 10/589,000

Filed: August 10, 2006

Intl. Application No.: PCT/IL2005/000173

Intl. Filing Date: February 10, 2005

Title: COMPOSITIONS FOR TREATMENT OF CANCER AND INFLAMMATION
WITH CURCUMIN AND AT LEAST ONE NSAID



INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. § 1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

- [X] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311.

The enclosed statement is accompanied by [check one]:

- [] i. a certification in part (e) below as specified in 37 C.F.R. § 1.97(e), or
- [] ii. a check in the amount required by 37 C.F.R. § 1.17(p).
- [] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. § 1.113, or a notice of allowance under 37 C.F.R. § 1.311, but before payment of the issue fee.
[] Certification report(e) below; and
[] a check in the amount as required by § 1.17(p).
- [] d. The enclosed statement is being filed pursuant to 37 C.F.R. § 1.97(i), for placement in the file.
- [] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,
or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

[] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

And/or


[] h. Copies of the documents are not attached as allowed under 1.98(d)(1)(2). The earlier application is identified as:
Or Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH LAW GROUP

By:



Gary M. Nath
Registration No. 26,965
Susanne M. Hopkins
Registration No. 33,247
Customer No. 20529

Date: January 4, 2007

NATH LAW GROUP


112 South West Street

Alexandria, VA 22314

Phone: 703-548-6284

Fax: 703-683-8396

GMN/SMH/dd (IDS.revisedNov03)



JAN 04 2007

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Atty Docket
27627U Serial No.
10/589,000Applicant
ARBER, et al.Filing Date
August 10, 2006 Group Art Unit
unknown

U. S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	AA	6,573,290	3 Jun 2003	Love			17 May 2000
	AB	2002/0006445	17 Jan 2002	Gelber et al.			5 Jan 2001
	AC	6,673,843	6 Jan 2004	Arbiser			30 Jun 1999
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Trans-lation
	AL	WO 03/105751 A2	24 Dec 2003	WIPO			N/A
	AM	WO 01/35956 A1	25 May 2001	WIPO			N/A
	AN	WO 03/007975 A1	30 Jan 2003	WIPO			N/A
	AO	WO 03/080044 A1	2 Oct 2003	WIPO			N/A
	AP	WO 03/103583 A2	18 Dec 2003	WIPO			N/A
	AR						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AS		Reddy, Bandaru S. et al., "Novel Approaches for Colon Cancer Prevention by Cyclooxygenase-2 Inhibitors" <u>Journal of Environmental Pathology, Toxicology and Oncology</u> , vol. 21, no. 2, pp. 155-164 (2002).
AT		Agarwal, B. et al., "Cox-2 is needed by tot sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells", <u>Apoptosis</u> , vol. 8, no. 6, pp. 649-654 (2003).
AU		

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant.